Aliskiren reduces albuminuria after kidney transplantation
Abstract
Background: The renoprotective effects of agents inhibiting the renin-angiotensin system in renal transplant recipients have been supposed but not finally proven. We performed a double-blind, placebo and losartan controlled, cross-over study to evaluate the influence of aliskiren, direct renin inhibitor on albuminuria and other surrogate markers of kidney injury in patients after renal transplantation. The safety of this therapy was also evaluated. Method: 16 of 18 patients (12M, 4F), 48.3 ± 9.0 years, 57.7 ± 9.1 months after kidney transplantation, with hypertension and stable serum creatinine 1.4±0.08 without proteinuria, completed the protocol. Each patient underwent two 8-week treatment periods (one with aliskiren 150 mg and one with losartan 50 mg) in random order, allowing an 8-week placebo washout between them. Results: Aliskiren decreased 24h systolic and 24h diastolic blood pressure as compared to placebo (post hoc: p=0.009 and p=0.003). Aliskiren decreased albuminuria more effectively than placebo as well (post hoc: p=0.032). There were no differences between aliskiren and losartan in these regards. The influence of aliskiren on N-acetyl-β-D-glucosaminidase, transforming growth factor β-1 and 15-F2t-isoprostanes urine excretions was not significant. Serum potassium, creatinine, eGFR and trough blood cyclosporine or tacrolimus level were unaffected. A significant but not clinically relevant decrease in haemoglobin level after aliskiren was observed. Conclusion: Aliskiren decreases albuminuria in renal transplant recipients with clinically minimal side effects.References
Al-Harbi NO, Imam F, Al-Harbi MM, Iqbal M, Nadeem A, Al-Shahrah OA, Korashy HM, Al-Hosaini KA, Ahmed M, Bahashwar S (2014) Treatment with aliskiren ameliorates tacrolimus-induced nephrotoxicity in rats. J Renin Angiotensin Aldosterone Syst. doi: 10.1177/1470320314530178
Bailie GR, Uhlig K, Levey AS (2005) Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy 25: 491–502
Djamali A, and Samaniego M (2009) Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. Transplantation 88: 1149–1156. doi: 10.1097/TP.0b013e3181bcccea
Fernandez-Fresnedo G, Escallada R, Rodrigo E, De Francisco AL, Cotorruelo JG, Sanz De Castro S, Zubimendi JA, Ruiz JC, Arias M (2002) The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 73: 1345–1348
Fernandez-Fresnedo G, Plaza JJ, Sanchez-Plumed J, Sanz-Guajardo A, Palomar-Fontanet R, Arias M (2004) Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 19, iii47–iii51
Gansevoort R, De Zeeuw D, De Jong P (1994) Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 45: 861–867
Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R (2006) Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889–899. doi: 10.1681/ ASN.2005090955
Ibrahim HN, Jackson S, Connaire J, Matas A, Ney A, Najafian B, West A, Lentsch N, Ericksen J, Bodner J, Kasiske B, Mauer M (2014).Angiotensin II blockade in kidney transplant recipients. J Am Soc Nephrol 24: 320–327. doi: 10.1681/ASN.2012080777
Komenda P, Rigatto C, Tangri N (2014). Estimated glomerular filtration rate and albuminuria: diagnosis, staging, and prognosis. Curr Opin Nephrol Hypertens 23: 251–257. doi: 10.1097/01. mnh.0000444910.55665.e8
Liu Y, Chen K, Kou X, Han Y, Zhou L, Zeng C (2013) Aliskiren and amlodipine in the management of essential hypertension: metaanalysis of randomized controlled trials. PLoS One 8: e70111. doi: 10.1371/journal.pone.0070111
Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Slawinska- Morawska M, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B (2013a) Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial. Int Urol Nephrol 44: 1763–1770
Lizakowski S, Tylicki L, Rutkowski B (2013b) Direct renin inhibition – a promising strategy for renal protection? Med Sci Monit 19: 451– 457. doi: 10.12659/MSM.883949
Opelz G, Dohler B (2014) Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation 97: 310–315. doi: 10.1097/01.TP.0000437672.78716.28
Opelz G, Zeier M, Laux G, Morath C, Dohler B (2006) No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 17: 3257–3262. doi: 10.1681/ASN.2006050543
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA (2012) Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204–2213. doi: 10.1056/NEJMoa1208799
Paul LC (1999). Chronic allograft nephropathy: An update. Kidney International 56: 783–793
Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH (2009) Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 32: 1873–1879. doi: 10.2337/dc09-0168
Philipp T, Martinez F, Geiger H, Moulin B, Mourad G, Schmieder R, Lievre M, Heemann U, Legendre C (2010) Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 25: 967– 976. doi: 10.1093/ndt/gfp581
Price R (1982) Urinary enzymes, nephrotoxicity and renal disease. Toxicol 23, 99-134.
Renke M, Knap N, Tylicki L, Rutkowski P, Lizakowski S, Wozniak M, Rutkowski B (2013) Isoprostanes – important marker of the oxidative stress estimation in patients with chronic kidney disease. Pol Merkur Lekarski 34: 14–17 (in Polish)
Roberts MA (2014) Commentary on the KDIGO Clinical Practice Guideline for the management of blood pressure in chronic kidney disease. Nephrology (Carlton) 19: 53–55. doi: 10.1111/nep.12168
Rusai K, Schmaderer C, Hermans JJ, Lutz J, Heemann U, Baumann M (2011) Direct renin inhibition in a rat model of chronic allograft injury. Transplantation 92: 999–1004. doi: 10.1097/ TP.0b013e318230c05b
Sharma VK, Bologa RM, Xu GP, Li B, Mouradian J, Wang J, Serur D, Rao V, Suthanthiran M (1996) Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 49: 1297–1303
Sherman R, Drayer D, Leyland-Jones B, Reidenberg M (1983) Nacetyl- D-glucosaminidase and beta-2-microglobulin; their urinary excretion in patients with renal parenchymal disease. Arch Intern Med 143: 1183–1185
Solez K, Vincenti F, Filo RS (1998) Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 66: 1736– 1740
Szeto CC, Kwan BC, Chow KM, Leung CB, Li PK (2013) The safety and short-term efficacy of aliskiren in the treatment of immunoglobulin a nephropathy – a randomized cross-over study. PLoS One 8: e62736. doi: 10.1371/journal.pone.0062736.
Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B (2007) Renal allograft protection with angiotensin II type 1 receptor antagonists. Am J Transplant 7: 243–248. doi: 10.1111/j.1600- 6143.2006.01588.x
Tylicki L, Biedunkiewicz B, Chamienia A, Wojnarowski K, Zdrojewski Z, Rutkowski B (2006) Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. Transplantation 81: 52–56
Tylicki L, Habicht A, Watschinger B, Horl W (2003). Treatment of hypertension in renal transplant recipients. Curr Opin Urol 13: 91–98. doi: 10.1097/01.mou.0000058634.64616.08
Tylicki L, Larczynski W, Rutkowski B (2005) Renal protective effects of the renin-angiotensin-aldosterone system blockade: from evidence-based approach to perspectives. Kidney Blood Press Res 28: 230–242. doi: 10.1159/000087842
Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Copyright for all published papers © stays with the authors.
Copyright for the journal: © Polish Biochemical Society.
